{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-023381","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.866784+00:00","generated_at":"2026-06-13T17:13:37.945041+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"MoonLake's sonelokimab hits HiSCR75 with 29 ppt delta (p=0.0002) in Phase 2 HS trial","bullets":["Primary endpoint HiSCR75 met with 29 ppt delta vs placebo (p=0.0002) at week 12.","HiSCR50 achieved 38 ppt delta (p<0.0001), highest delta observed for any molecule in HS.","Secondary endpoints including HiSCR90, IHS4, and patient-reported pain/quality of life met statistical significance.","Safety profile consistent with known IL-17 inhibitor class; no new safety signals observed.","Dose of 120mg performed similarly to 240mg; 120mg considered optimal for further development."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-023381","json":"https://secwatch.observer/filing/0001628280-23-023381.json","markdown":"https://secwatch.observer/filing/0001628280-23-023381.md","text":"https://secwatch.observer/filing/0001628280-23-023381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000162828023023381/0001628280-23-023381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000162828023023381/mltx-20230626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:13:37.945041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}